Rajesh Kumar

– Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell biology

– Company also primed to advance additional programs, including a pan-inflammasome inhibitor

Poster presentations to feature research on leveraging artificial intelligence and machine learning methods to decode the gut-brain axis, innate immunity, and neuroinflammation for target identification and drug discovery